Medscape Education Leverages AI for Hematology at EHA 2026
Decision brief
Answer first · skim in under a minute
Medscape Education will host a session on the practical and ethical use of AI in Hematology and Oncology at EHA 2026. This initiative aims to equip hematologists with the knowledge to navigate the evolving landscape of AI in their specialty.
Medscape Education plans a hematology-focused AI ethics symposium on June 11, 2026, during the European Hematology Association congress. The session sits beside growing European Society for Medical Oncology (ESMO) guidance on validating AI-based oncology tools. For medical affairs teams, the signal is simple: hematology AI literacy is now a congress product that sponsors will watch closely.
Contents10 sections
Key Takeaways
- Medscape said it will host Future-Ready Hematologists: Practical and Ethical Use of AI in Hematology and Oncology on June 11, 2026, at EHA 2026.
- Faculty named in the release include Jakob N. Kather, Chan Cheah, and Matthew Lunning.
- Agenda themes include large language models for guideline interpretation, workflow uses, and ESMO EBAI / ELCAP-style responsible AI principles.
- ESMO’s EBAI framework sets validation expectations for AI-based oncology biomarkers and is separate from any vendor CME claim.
What did Medscape announce for EHA 2026?
In a Business Wire release, Medscape Education said it will launch the Future-Ready Hematologists symposium on June 11, 2026, during EHA 2026. The stated goal is practical and ethical AI frameworks for hematology and oncology clinicians.
Named chairs and faculty include Prof. Jakob N. Kather (Technical University Dresden / NCT Heidelberg), Prof. Chan Cheah (Sir Charles Gairdner Hospital, Perth), and Prof. Matthew Lunning (University of Nebraska Medical Center). Those affiliations are as stated by Medscape; they are not independent trial results.
Which AI topics will the hematology session cover?
The release lists four teaching pillars: large language models for guideline interpretation and treatment decisions; emerging AI uses in hematology and oncology workflows; practical implementation of ESMO, EBAI, and ELCAP guidance; and core principles of responsible AI adoption.
Medscape also positions Medscape AI as a member-facing tool grounded in cited clinical sources. That is company marketing language inside the same wire. Treat it as product context, not as peer-reviewed efficacy evidence.
How does ESMO EBAI frame responsible AI in oncology?
ESMO has published society updates on validation requirements for AI-based biomarkers in oncology, known as EBAI. The framework stresses clear ground truth, performance versus standard of care, and generalizability beyond a single institution.
That guidance is useful context for why an EHA education session keeps citing ESMO AI principles. It does not mean the Medscape symposium itself validates any biomarker algorithm.
What should BD and medical affairs take from this?
Congress AI literacy programs can change how specialists ask about companion diagnostics, real-world evidence, and label claims. Track whether competitors sponsor similar sessions. Check faculty industry ties. Do not assume attendance equals prescribing change.
Hematology moves fast. New trial readouts arrive every congress cycle. AI tools that summarize guidelines may help clinicians keep up. They can also invent citations if models are not grounded. That is why ESMO-style validation rules matter in education decks.
- Session date: June 11, 2026
- Congress: EHA 2026
- Sponsor/educator: Medscape Education
- External framework cited: ESMO EBAI
- Wire source date context: June 2026 Medscape release
What FDA AI device resources remain relevant?
U.S. teams supporting global hematology brands should also monitor FDA materials on AI/ML-enabled medical devices when education slides discuss decision-support software. European congress teaching and U.S. device regulation are different lanes. Keep claims matched to each authority in every slide deck.
What remains unproven?
The wire does not report randomized evidence that Medscape AI or the EHA session improves hematologic outcomes. It also does not prove lower medical error rates. It does not prove better guideline adherence. Location details in secondary reprints can vary. Use the Medscape Business Wire text for the symposium claim. Treat venue city claims as secondary unless an allowlisted primary confirms them.
For readers, the practical next step is simple. Compare any AI hematology pitch against ESMO EBAI checks. Ask for ground truth, performance data, and proof the tool works outside one hospital system. Ask who audited the training data. Ask what happens when the model is wrong at the bedside.
Related NovaPharma coverage
- SFEE on Greek Patient Access Delays
- Bladder Cancer Care Education and Awareness
- Gilead Hepcludex FDA Approval
Frequently Asked Questions
What AI hematology session is Medscape running at EHA 2026?
Medscape Education said it will present Future-Ready Hematologists: Practical and Ethical Use of AI in Hematology and Oncology on June 11, 2026, during the European Hematology Association congress.
What is ESMO EBAI guidance?
ESMO published Basic Requirements for AI-based Biomarkers in Oncology (EBAI) to define validation expectations such as ground truth, performance versus standard of care, and generalizability.
Does the Medscape session prove clinical outcomes from AI tools?
No. The Business Wire announcement describes an educational symposium and product positioning for Medscape AI. It does not report controlled outcome trials showing better hematology survival from AI use.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
